Active Ingredient: bictegravir, emtricitabine, and tenofovir alafenamide
Strength: 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF/ 30 mg of BIC, 120 mg of FTC, and 15 mg of TAF
Dosage Form: Tablet
Mechanism of Action: HIV reverse transcriptase inhibitors
First Approval: US (07 Feb 2018), EU (25 Jun 2018)
Revenue1
Gilead's HIV drug, Biktarvy has…
